share_log

Bristol-Myers Squibb | 4: Statement of changes in beneficial ownership of securities-Officer Hoch Lynelle

SEC announcement ·  Mar 12 20:04
Summary by Moomoo AI
On March 10, 2024, Lynelle Hoch, President of Cell Therapy Org. at Bristol-Myers Squibb (BMY), completed a series of transactions involving the company's common stock. Hoch acquired a total of 4,351 shares through the exercise of derivative securities at no cost. On the same day, Hoch disposed of 2,625 shares through various transactions, including the payment of exercise price or tax liability by delivering or withholding securities, with some shares sold at a price of $53.79 each. The total market value of the disposed shares amounted to $70,357.32. After these transactions, Hoch's direct holdings in Bristol-Myers Squibb common stock amounted to 1,726 shares.
On March 10, 2024, Lynelle Hoch, President of Cell Therapy Org. at Bristol-Myers Squibb (BMY), completed a series of transactions involving the company's common stock. Hoch acquired a total of 4,351 shares through the exercise of derivative securities at no cost. On the same day, Hoch disposed of 2,625 shares through various transactions, including the payment of exercise price or tax liability by delivering or withholding securities, with some shares sold at a price of $53.79 each. The total market value of the disposed shares amounted to $70,357.32. After these transactions, Hoch's direct holdings in Bristol-Myers Squibb common stock amounted to 1,726 shares.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more